Skip to main content

Table 2 Summary of best confirmed response to treatment with ixazomib-Rd and placebo-Rd

From: Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Best confirmed response, n (%) Ixazomib-Rd (n = 57) Placebo-Rd (n = 58) p value (unstratified Cochran–Mantel–Haenszel test)
ORR (≥PR) (95% CI) 32 (56) (42–69) 18 (31) (20–45) 0.007
 ≥VGPR rate (95% CI) 14 (25) (14–38) 7 (12) (5–23) 0.084
CR 3 (5) 0 0.078
PR 29 (51) 18 (31)
 VGPR 11 (19) 7 (12)
SD 17 (30) 17 (29)
PD 6 (11) 15 (26)
Not evaluable 2 (4) 8 (14)
  n = 32 n = 18  
Time to response, median (IQR) 1.0 (0.9–1.8) 1.0 (0.9–1.9)
DOR, median (95% CI) 7.4 months (6.21–NE) 5.6 months (2.73–9.46)
Responders who had not progressed at data cut-off, n (%) 19 (59) 7 (39)  
  1. Time to response: time from first documentation of PR or better to first documentation of PD; Duration of response: time from first documentation of partial response or better to first documentation of progression
  2. Abbreviations: CR complete response, DOR duration of response, NE not estimable, ORR overall response rate, PD progressive disease, PR partial response, SD stable disease, VGPR very good partial response